Specific tumor cell targeting by a recombinant MVA expressing a functional single chain antibody on the surface of intracellular mature virus (IMV) particles

Viral Immunology

Volumn 20, Issue 4, 2007, Pages 664-671

  Paul, Stéphane ^a   Geist, Michel ^a   Dott, Karine ^a   Snary, David ^b   Taylor Papadimitriou, Joyce ^b   Acres, Bruce ^a   Silvestre, Nathalie ^a   Kieny, Marie Paule ^c   Balloul, Jean Marc ^a  

^a TRANSGENE S A   (France)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CELL ANTIGEN; HYBRID PROTEIN; MEMBRANE PROTEIN; MUCIN 1; PROTEIN P14;

A27L GENE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CARCINOMA; CELL SPECIFICITY; CELL SURFACE; CONTROLLED STUDY; CYTOLYSIS; GENE; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; MODIFIED VACCINIA VIRUS ANKARA; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL; TUMOR IMMUNITY; VACCINIA VIRUS; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, NEOPLASM; CARRIER PROTEINS; CELL LINE, TUMOR; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MICE; MUCINS; NEOPLASMS; RECOMBINANT FUSION PROTEINS; VACCINIA; VACCINIA VIRUS; VIRAL FUSION PROTEINS;

VACCINIA VIRUS;

EID: 37549058766     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2007.0058     Document Type: Article

References (28)

1. Bryan TM, Englezou A, Gupta J, Bacchetti S, and Reddel RR: Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995;14:4240-4248.
2. Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R, and Lamport D: Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987;47:5476-5482.
3. Carroll MW, and Moss B: E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses. Biotechniques 1995;19:352-354.
4. Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss B, and Restifo NP: Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 1997;15: 387-394.
5. Cavallo F, Martin-Fontecha A, Bellone M, et al.: Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol 1995;25:1154-1162.
6. Chung CS, Hsiao JC, Chang YS, and Chang W: A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J Virol 1998;72:1577-1585.
7. Dokurno P, Bates PA, Band HA, et al.: Crystal structure at 1.95 A resolution of the breast tumour-specific antibody SM3 complexed with its peptide epitope reveals novel hypervariable loop recognition. J Mol Biol 1998;284:713-728.
8. Doms RW, Blumenthal R, and Moss B: Fusion of intraand extracellular forms of vaccinia virus with the cell membrane. J Virol 1990;64:4884-4892.
9. Drexler I, Heller K, Wahren B, Erfle V, and Sutter G: Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998;79:347-352.
10. Falkner FG, and Moss B: Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol 1988;62:1849-1854.
11. Galmiche MC, Rindisbacher L, Wels W, Wittek R, and Buchegger F: Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting. J Gen Virol 1997;78:3019-3027.
12. Hsiao JC, Chung CS, and Chang W: Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol 1999;73:8750-8761.
13. Kain R, Angata K, Kerjaschki D, and Fukuda M: Molecular cloning and expression of a novel human trans-Golgi network glycoprotein, TGN51, that contains multiple tyrosine-containing motifs. J Biol Chem 1998;273:981-988.
14. Katz E, Wolffe EJ, and Moss B: The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions. J Virol 1997;71:3178-3187.
15. Lin CL, Chung CS, Heine HG, and Chang W: Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo. J Virol 2000;74:3353-3365.
16. Mahnel H, and Mayr A: [Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA]. Berl Munch Tierarztl Wochenschr 1994;107:253-256.
17. Mayr A, Stickl H, Muller HK, Danner K, and Singer H: Der Pockenimpstamm MVA: Marker, genetische Struktur, Erfahrungen mit der parenteralen Schutzimpfung und Verhalten im abwehrgeschwachten Organismus. Zbl Bakt Hyg B 1978;167:375-390.
18. Mbiguino A, and Menezes J: Purification of human respiratory syncytial virus: superiority of sucrose gradient over percoll, renografin, and metrizamide gradients. J Virol Methods 1991;31:161-170.
19. Moss B: Poxviridae and Their Replication. Raven Press, New York, 1990.
20. Moss B, Carroll MW, Wyatt LS, et al.: Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 1996;397:7-13.
21. Paul S, Bizouarne N, Paul A, Price MR, Hansson GC, Kieny MP, and Acres RB: Lack of evidence for an immunosuppressive role for MUC1. Cancer Immunol Immunother 1999;48:22-28.
22. Paul S, Snary D, Hoebeke J, et al.: Targeted macrophage cytotoxicity using a nonreplicative live vector expressing a tumor-specific single-chain variable region fragment . Hum Gene Ther 2000;11:1417-1428.
23. Peplinski GR, Tsung K, and Norton JA: Vaccinia virus for human gene therapy. Surg Oncol Clin North Am 1998;7:575-588.
24. Purow B, and Staveley-O'Carroll K: Targeting of vaccinia virus using biotin-avidin viral coating and biotinylated antibodies. J Surg Res 2005;123:49-54.
25. Smith GL, and Law M: The exit of vaccinia from infected cells. Virus Res 2004;106:189-197.
26. Spehner D, Drillien R, Proamer F, et al.: Enveloped virus is the major virus form produced during productive infection with the modified vaccinia virus Ankara strain. Virology 2000;273:9-15.
27. Sutter G, and Moss B: Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 1992;89:10847-10851.
28. Vazquez M I, and Esteban M: Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus. J Virol 1999;73:9098-9109.